Inhibition of the prostaglandin D


Journal

Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777

Informations de publication

Date de publication:
07 2020
Historique:
received: 13 09 2019
accepted: 28 02 2020
pubmed: 1 5 2020
medline: 5 10 2021
entrez: 1 5 2020
Statut: ppublish

Résumé

Inflammatory signals and increased prostaglandin synthesis play a role during the development of diabetes. The prostaglandin D Human islets were exposed to PGD PGD Inhibition of GPR44 in human islets has the potential to improve islet function and survival rate under inflammatory and hyperglycaemic stress. This may have implications for better survival rate of islets following transplantation.

Identifiants

pubmed: 32350565
doi: 10.1007/s00125-020-05138-z
pii: 10.1007/s00125-020-05138-z
pmc: PMC7286861
doi:

Substances chimiques

DNA-Binding Proteins 0
Insulin 0
Receptors, Immunologic 0
Receptors, Prostaglandin 0
TFDP2 protein, human 0
Transcription Factors 0
Glucose IY9XDZ35W2
Prostaglandin D2 RXY07S6CZ2
prostaglandin D2 receptor XZF106QU24

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1355-1367

Subventions

Organisme : Research Council of Norway - Center of Excellence
ID : 262613
Pays : International
Organisme : South Eastern Norway Regional Health Authority
ID : 2012031
Pays : International

Références

J Pharmacol Exp Ther. 2003 Aug;306(2):463-70
pubmed: 12721327
Pharmacol Ther. 2004 Aug;103(2):147-66
pubmed: 15369681
Diabetologia. 2006 Dec;49(12):2959-68
pubmed: 17033838
Bioorg Med Chem Lett. 2011 Nov 1;21(21):6288-92
pubmed: 21944852
J Biol Chem. 2014 Oct 3;289(40):27410-7
pubmed: 25122761
Biochim Biophys Acta. 1996 Aug 28;1313(2):106-10
pubmed: 8781557
Acta Endocrinol (Copenh). 1975 Jun;79(2):266-74
pubmed: 1173486
Endocrinology. 2009 Dec;150(12):5284-93
pubmed: 19837872
J Proteomics. 2012 May 17;75(9):2611-20
pubmed: 22465717
Cell Transplant. 2008;17(12):1305-13
pubmed: 19364068
J Clin Endocrinol Metab. 2008 Oct;93(10):4065-74
pubmed: 18664535
Diabetes. 1983 Jun;32(6):509-15
pubmed: 6354779
J Biol Chem. 2012 Sep 14;287(38):32246-53
pubmed: 22822059
J Biol Chem. 2006 Sep 29;281(39):29330-6
pubmed: 16873378
Diabetes. 2009 Jul;58(7):1595-603
pubmed: 19509022
PLoS One. 2018 Dec 17;13(12):e0208998
pubmed: 30557325
Diabetes. 2011 Feb;60(2):525-36
pubmed: 20980460
Sci Rep. 2017 May 8;7(1):1575
pubmed: 28484241
Br J Pharmacol. 2013 Apr;168(7):1626-38
pubmed: 23146091
Transplantation. 2008 Jul 27;86(2):360-3
pubmed: 18645503
Diabetes. 1998 Mar;47(3):316-23
pubmed: 9519734
J Leukoc Biol. 2005 May;77(5):587-97
pubmed: 15728243
Diabetes. 2013 Jun;62(6):1904-12
pubmed: 23349487
PLoS One. 2015 Mar 20;10(3):e0121204
pubmed: 25793295
Drug Des Devel Ther. 2016 Aug 31;10:2759-70
pubmed: 27621597
Transplantation. 2011 Mar 27;91(6):677-83
pubmed: 21248660
Diabetes. 2001 Jun;50(6):1290-301
pubmed: 11375329
Am J Transplant. 2009 Sep;9(9):2119-25
pubmed: 19706025
Cell Biochem Biophys. 2007;48(2-3):191-9
pubmed: 17709889
Front Endocrinol (Lausanne). 2015 Jan 13;5:237
pubmed: 25628604
Diabetes. 1983 Mar;32(3):231-4
pubmed: 6337902
J Cell Commun Signal. 2017 Jun;11(2):105-116
pubmed: 28132118
J Mol Med (Berl). 2003 Aug;81(8):455-70
pubmed: 12879149
Cell Transplant. 2016;25(3):503-15
pubmed: 26084381
Acta Diabetol. 2016 Jun;53(3):413-21
pubmed: 26467464
Diabetes. 1987 Sep;36(9):1047-53
pubmed: 2886385
Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1788-93
pubmed: 9465095
Curr Diabetes Rev. 2013 Jan 1;9(1):25-53
pubmed: 22974359
J Transplant. 2012;2012:230870
pubmed: 22919462
Curr Diabetes Rev. 2015;11(3):135-43
pubmed: 25777058
J Clin Invest. 2002 Dec;110(12):1839-47
pubmed: 12488434
Diabetes. 2018 Feb;67(2):182-192
pubmed: 29208633
Diabetes. 2017 May;66(5):1334-1345
pubmed: 28137793
Diabetes. 2008 Oct;57(10):2745-54
pubmed: 18820214

Auteurs

Shadab Abadpour (S)

Department of Transplant Medicine and Institute for Surgical Research, Oslo University Hospital, Sognsvannsveien 20, 0027, Oslo, Norway.
Hybrid Technology Hub, Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.

Björn Tyrberg (B)

Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Peppredsleden 1, 431 83 Mölndal, Gothenburg, Sweden.

Simen W Schive (SW)

Department of Transplant Medicine and Institute for Surgical Research, Oslo University Hospital, Sognsvannsveien 20, 0027, Oslo, Norway.

Charlotte Wennberg Huldt (CW)

Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Peppredsleden 1, 431 83 Mölndal, Gothenburg, Sweden.

Peter Gennemark (P)

Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Peppredsleden 1, 431 83 Mölndal, Gothenburg, Sweden.
Department of Biomedical Engineering, University of Linköping, Linköping, Sweden.

Erik Ryberg (E)

Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Peppredsleden 1, 431 83 Mölndal, Gothenburg, Sweden.

Tina Rydén-Bergsten (T)

Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Peppredsleden 1, 431 83 Mölndal, Gothenburg, Sweden.

David M Smith (DM)

Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Peppredsleden 1, 431 83 Mölndal, Gothenburg, Sweden.
Hit Discovery, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Olle Korsgren (O)

Department of Immunology, Genetics and Pathology, Science for Life Laboratory, University of Uppsala, Uppsala, Sweden.

Stanko Skrtic (S)

Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Peppredsleden 1, 431 83 Mölndal, Gothenburg, Sweden.
Institute of Medicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Hanne Scholz (H)

Department of Transplant Medicine and Institute for Surgical Research, Oslo University Hospital, Sognsvannsveien 20, 0027, Oslo, Norway. hanne.scholz@medisin.uio.no.
Hybrid Technology Hub, Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway. hanne.scholz@medisin.uio.no.

Maria Sörhede Winzell (MS)

Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Peppredsleden 1, 431 83 Mölndal, Gothenburg, Sweden. maria.sorhede-winzell@astrazeneca.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH